Auspex Pharmaceuticals 10-K 16 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 27, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ASPX
Entity Registrant Name	Auspex Pharmaceuticals, Inc.
Entity Central Index Key	1454189
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		31,815,187
Entity Public Float			$170,000,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$29,793	$36,650
Marketable securities	115,148	0
Prepaid expenses and other current assets	5,711	242
Total current assets	150,652	36,892
Deferred offering costs	111	1,817
Property and equipment, net	177	26
Other assets	205	137
Total assets	151,145	38,872
Current liabilities:
Accounts payable	6,705	1,365
Accrued liabilities	4,663	2,127
Total current liabilities	11,368	3,492
Long-term debt, less discount of $405 and $580, respectively	14,595	14,420
Preferred stock warrant liability		3,975
Other long-term liabilities	311	77
Total liabilities	26,274	21,964
Commitments and contingencies (Note 10)
Convertible preferred stock, par value $0.0001; 10,000,000 and 68,694,006 shares authorized at December 31, 2014 and December 31, 2013, respectively; none and 64,790,302 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively; $0 and $91,726 liquidation preference at December 31, 2014 and December 31, 2013, respectively		81,846
Equity (deficit):
Common stock, par value $0.0001; 200,000,000 and 86,500,000 shares authorized at December, 31, 2014 and December, 31, 2013, respectively; 27,748,264 and 1,128,702 issued and 27,123,554 and 173,147 outstanding, excluding 624,710 and 955,555 shares subject to repurchase at December, 31, 2014 and December, 31, 2013, respectively	3
Additional paid-in capital	246,138	542
Accumulated deficit	-125,054	-65,480
Accumulated other comprehensive income		0
Total Auspex stockholders’ equity (deficit)	121,087	-64,938
Noncontrolling interest in variable interest entity	3,784
Total equity (deficit)	124,871	-64,938
Total liabilities, convertible preferred stock and equity (deficit)	$151,145	$38,872

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Debt Instrument, Unamortized Discount	$405	$580
Convertible Preferred stock, par value	$0.00	$0.00
Convertible Preferred stock, shares authorized	10,000,000	68,694,006
Convertible Preferred stock, shares issued	0	64,790,302
Convertible Preferred stock, shares outstanding	0	64,790,302
Convertible Preferred stock, liquidation preference	$0	$91,726
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	86,500,000
Common stock, shares issued	27,748,264	1,128,702
Common stock, shares outstanding	27,123,554	173,147
Common stock, shares subject repurchase	624,710	955,555

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Operating expenses:
Research and development	$37,727		$10,003		$11,741
General and administrative	12,529		3,189		1,688
Total operating expenses	50,256		13,192		13,429
Operating loss	-50,256		-13,192		-13,429
Other (expense) income:
Interest expense	-2,612		-248		-1,293
Interest income	1,185				1
Other financing expense			-258		-196
Change in fair value of preferred stock warrant liability	-3,634		-1,931		-195
Loss on consolidation of variable interest entity	-4,269
Other, net	51
Total other (expense) income, net	-9,279		-2,437		-1,683
Net loss	-59,535		-15,629		-15,112
Net income attributed to noncontrolling interest	39
Net loss attributable to Auspex shareholders	($59,574)		($15,629)		($15,112)
Net loss per share attributable to Auspex shareholders, basic and diluted	($2.68)	[1],[2],[3]	($371)	[1],[2],[3]	($114,485)	[3]
Weighted-average common shares outstanding, basic and diluted	22,195,518		42,112		132
[1]	Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year.
[2]	In the first quarter of 2014, the Company issued 8,050,000 shares of common stock as part of its initial public offering. Further, the Company issued an additional 3,622,500 shares of common stock pursuant to a follow-on offering in July 2014. As a result, there is a lack of comparability in the basic and diluted net loss per share amount for the periods presented.
[3]	As a result of the issuance of common stock pursuant to public offerings in the first and third quarters of 2014, there is a lack of comparability in the per share amounts between the periods presented. Please see Note 2 of the Notes to Consolidated Financial Statements for further discussion.

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Net loss	($59,535)	($15,629)	($15,112)
Other comprehensive income (loss):
Unrealized gains on available-for-sale securities, net	5
Foreign currency translation adjustment	-5
Comprehensive loss	-59,535	-15,629	-15,112
Comprehensive gain attributable to noncontrolling interest	39
Comprehensive loss attributable to Auspex	($59,574)	($15,629)	($15,112)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net loss	($59,535)	($15,629)	($15,112)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	49	12	30
Loss on disposal of assets	21
Change in fair value of preferred stock warrant liability	3,634	1,931	195
Amortization of debt discount on notes payable	175	126	813
Amortization of premium on investment	895
Other financing expense		258	196
Stock-based compensation	3,807	300	82
Noncash interest expense on convertible notes payable			480
Loss on consolidation of variable interest entity	4,269
Change in operating assets and liabilities:
Prepaid expenses and other current assets	-5,460	-88	12
Other assets	1,642	-104	-2
Accounts payable and accrued expenses	7,596	1,893	633
Net cash used in operating activities	-42,907	-11,301	-12,673
Investing activities
Purchases of marketable securities	-155,791
Maturities of marketable securities	39,753
Purchases of property and equipment	-221	-14	-33
Net cash used in investing activities	-116,259	-14	-33
Financing activities
Proceeds from exercise of warrants and stock options and stock issuances under employee stock purchase plan	688	240
Proceeds from the issuance of common stock, net of fees	151,633	9
Proceeds from term loans		20,000
Term loan origination fees		-100
Repayment of term loans		-5,000
Proceeds from the issuance of convertible preferred stock, net of issuance costs		29,819	7,823
Deferred offering costs	-12	-1,282
Proceeds from issuance of convertible debt, net			6,000
Net cash provided by financing activities	152,309	43,686	13,823
Net (decrease) increase in cash and cash equivalents	-6,857	32,371	1,117
Cash and cash equivalents at beginning of period	36,650	4,279	3,162
Cash and cash equivalents at end of period	29,793	36,650	4,279
Supplemental disclosure of cash flow information
Cash paid for interest expense	1,237	81
Conversion of notes and accrued interest to preferred stock			9,493
Accrued public offering costs		$535

STATEMENTS_OF_CONVERTIBLE_PREF

STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Income	Noncontrolling interest in variable interest entity	Initial Public Offering	Initial Public Offering	Initial Public Offering	Follow-on Offering	Follow-on Offering	Follow-on Offering	Series A-D, Convertible Preferred Stock	Series D convertible preferred stock	Series E convertible preferred stock
In Thousands, except Share data								Common Stock	Additional Paid-in Capital		Common Stock	Additional Paid-in Capital
Balance at Dec. 31, 2011	($34,588)		$151	($34,739)									$33,899
Balance , shares at Dec. 31, 2011		132											20,701,224
Stock issued during period, value, new issues														6,456
Stock issued during period, shares, new issues														9,280,745
Stock issued during period, value, conversion of convertible securities														9,493
Stock issued during period, shares, conversion of convertible securities														11,012,456
Stock-based compensation	82		82
Net (loss) income	-15,112			-15,112
Balance at Dec. 31, 2012	-49,618		233	-49,851									49,848
Balance , shares at Dec. 31, 2012		132											40,994,425
Stock issued during period, value, new issues														10,456	19,363
Stock issued during period, shares, new issues														12,180,978	11,336,481
Reclassification of tranche right upon issuance of stock														1,820
Exercise of preferred stock warrants													359
Exercise of preferred stock warrants, shares													278,418
Exercise of common stock options and vesting of early exercised stock options	4		4
Exercise of common stock options and vesting of early exercised stock options, shares		5,555
Issuance of restricted stock awards	5		5
Issuance of restricted stock awards, shares		167,460
Stock-based compensation	300		300
Net (loss) income	-15,629			-15,629
Balance at Dec. 31, 2013	-64,938		542	-65,480									81,846
Balance , shares at Dec. 31, 2013		173,147											64,790,302
Stock issued during period, value, new issues							86,659	1	86,658	64,974	1	64,973
Stock issued during period, shares, new issues								8,050,000			3,622,500
Reclassification of warrant liability as equity	7,609		7,609
Exercise of common stock options and vesting of early exercised stock options	227		227
Exercise of common stock options and vesting of early exercised stock options, shares		261,197
Exercise of common stock warrants	183		183
Exercise of common stock warrants, shares		269,894
Stock issuances under employee stock purchase plan, value	278		278
Stock issuances under employee stock purchase plan		24,615
Restricted stock vesting	23	324,365	23
Stock-based compensation	3,807		3,807
Cumulative translation adjustment	-5				-5
Unrealized gain on marketable securities	5				5
Consolidation of variable interest entity	3,745					3,745
Net (loss) income	-59,535			-59,574		39
Conversion of preferred shares to common shares	81,839	1	81,838										-81,846
Stock issued during period, value, new issues		14,397,836											-64,790,302
Balance at Dec. 31, 2014	$124,871	$3	$246,138	($125,054)		$3,784
Balance , shares at Dec. 31, 2014		27,123,554

STATEMENTS_OF_CONVERTIBLE_PREF1

STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) (Parenthetical) (USD $)	12 Months Ended		1 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2014	Jul. 31, 2014
Series D convertible preferred stock
Offering cost	$45	$177
Tranche liability		1,367
Series E convertible preferred stock
Offering cost	181
Initial Public Offering | Common Stock
Offering cost			9,942
Common stock, par value			$12
Follow-on Offering | Common Stock
Offering cost				$4,760
Common stock, par value				$19.25

Organization

Organization	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization
	Auspex Pharmaceuticals, Inc. (the “Company”) was founded on February 28, 2001 (“inception”), incorporated in California upon inception and subsequently reincorporated in Delaware in June 2007. The Company is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The Company’s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications.
	From inception through December 31, 2014, the Company has devoted substantially all of its efforts to research, product development, raising capital, and building corporate infrastructure and has not generated any revenues from its planned principal operations. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception, and, as of December 31, 2014, had an accumulated deficit of $125.1 million.
	The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company plans to continue to fund its losses from operations and capital funding needs through future debt and equity financing, or through collaborations or partnerships with other companies. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
	2. Summary of Significant Accounting Policies
	Basis of Presentation
	The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles and with the rules and regulations of the Securities and Exchange Commission (“SEC”) and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of convertible preferred stock warrants, equity awards and clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
	Basis of Consolidation
	The Company’s consolidated financial statements include the financial statements of the Company and a variable interest entity (“VIE”) for which the Company has been determined to be the primary beneficiary (see Note 9 for further discussion). All intercompany accounts between the Company and the VIE have been eliminated in consolidation. The Company will continue to assess its relationship with the VIE on an ongoing basis as circumstances requiring consolidation may change.
	Segment Reporting
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
	Reverse Stock Split
	On January 16, 2014, the Company effected a 1-for-4.5 reverse stock split of the Company’s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements have been retroactively adjusted to reflect the January 2014 reverse stock split for all periods presented.
	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash and highly liquid securities with maturities at the date of acquisition of ninety days or less. Investments with maturities at the date of acquisition of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, marketable securities, restricted cash, trade payables, accrued liabilities and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, trade payables and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based upon the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value. The fair value of marketable securities is based upon market prices quoted on the last day of the fiscal period or a fair value representing the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. See Note 3 for further discussion of fair value measurements.
	Convertible Preferred Stock Warrants
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company’s convertible preferred stock warrants were classified as liabilities, and the Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. In connection with the completion of the Company’s initial public offering (“IPO”) in February 2014, all the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As a result of the IPO and warrant conversion, the Company reclassified the warrant liability as stockholders’ equity because the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO date in February 2014, and recorded the $3,634,000 change in fair value as other income (expense) at that time.
	Stock-Based Compensation Expense
	The Company has stock-based compensation plans and an employee stock purchase plan, which are described in Note 8. As of December 31, 2014, the Company had issued both stock option awards and restricted stock units under its stock-based compensation plans and permitted eligible employees to participate in an employee stock purchase plan (“ESPP”) whereby shares of the Company’s common stock may be purchased at a discount. The Company accounts for stock option grants and participation in the ESPP using the Black-Scholes option pricing model.  Restricted stock awards are valued based on their fair market value at the time of grant. Further discussion of the expense related to these programs is provided below:
	Stock option awards. Stock options are valued using the Black-Scholes option pricing model. The Company values option awards on the date of grant or, if the awards are classified as liability awards, it revalues the awards each reporting period using this model until the awards are subsequently classified as equity awards, or otherwise vest or are cancelled. The Black-Scholes option pricing model involves a number of estimates, including the expected lives of stock options, the Company’s anticipated stock volatility and interest rates. The following table summarizes the weighted-average estimates the Company used in the Black-Scholes option pricing model for the years ended December 31, 2014, 2013 and 2012, to determine the grant-date fair value of stock options granted during each period for its stock option awards:
		Year Ended December 31,
		2014		2013		2012
	Risk free interest rate		1.40%		1.50%		1.00%
	Expected life in years	6.2 years		6.1 years		6.0 years
	Expected dividend yield		0.00%		0.00%		0.00%
	Expected volatility		87.20%		82.60%		94.30%
	The Company determines its risk-free interest rate assumption based on the U.S. Treasury yield for obligations with contractual lives similar to the expected lives of the Company’s share-based payment awards being valued. The weighted-average expected life of options is calculated using the simplified method, as prescribed by the SEC, due to the lack of relevant historical exercise data. Due to the Company’s limited historical stock price volatility data, the estimated volatility is determined by incorporating the historical stock price volatility of comparable companies whose shares prices are publicly available. The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future. Forfeitures are estimated based upon the historical and anticipated future experience.
	Based upon these assumptions, the Company has estimated the per share weighted-average grant date fair value of its options granted for the years ended December 31, 2014, 2013 and 2012 at $11.54, $0.55 and $0.63, respectively.
	Restricted stock awards. Restricted stock awards are valued based on the fair market value of the Company’s stock on the date of grant. The weighted-average grant date fair value of the RSUs granted in 2013 was $0.54. There were no restricted stock awards granted in 2014 or 2012.
	Employee Stock Purchase Plan. In 2014 the Company began permitting eligible employees to purchase shares of the Company’s common stock at a discount to the fair market value at semi-annual intervals. In determining the value of shares issued under the ESPP, the Company uses the Black-Scholes option pricing model and values the contributions at each purchase interval or when contributions are modified. The Black-Scholes inputs are determined in the same manner as for stock options and the weighted-average inputs used for the ESPP for the year ended December 31, 2014, were as follows:
		Year Ended December 31, 2014
	Risk free interest rate		0.20%
	Expected life in years	1.3 years
	Expected dividend yield		0.00%
	Expected volatility		82.00%
	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options, restricted stock and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Year Ended December 31,
		2014		2013		2012
	Research and development	$	1,832	$	89	$	43
	General and administrative		1,975		211		39
	Total stock-based compensation expense	$	3,807	$	300	$	82
	The total unrecognized stock-based compensation expense related to unvested stock options and restricted shares not yet vested at December 31, 2014, was approximately $13,848,000 to be recognized over a weighted-average period of approximately 39 months. The total unrecognized stock-based compensation expense related to the ESPP at December 31, 2014, was approximately $253,000, which is expected to be recognized over a weighted-average period of approximately 7 months.
	Research and Development
	The Company’s research and development expenses consist primarily of costs associated with clinical trials managed by the Company’s contract research organizations (“CROs”), salaries and related employee benefits, and costs associated with non-clinical activities, such as regulatory, drug development of product candidates, and pre-commercialization manufacturing expenses. The Company uses external service providers and vendors to conduct clinical trials, to manufacture product candidates to be used in clinical trials and to provide various other research and development related products and services. The Company accounts for research and development expenditures as incurred and accrues expenses based upon estimates of work performed, patient enrollment and experience with similar contracts.
	Patent Costs
	The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations.
	Property and Equipment
	Property and equipment, including leasehold improvements, are stated at cost or, if the assets are impaired, at fair value. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are generally as follows: five years for machinery and equipment; seven years for furniture and fixtures; three years for office equipment; and three years for computer equipment and software. Leasehold improvements are amortized over the shorter of their useful lives or the terms of the related leases. Asset lives are reviewed periodically to determine if appropriate and adjustments are made as necessary. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are expensed as incurred.
	For the years ended December 31, 2014, 2013 and 2012, the Company recorded depreciation expense on its property and equipment of $49,000, $12,000 and $30,000, respectively.
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Components of comprehensive income (loss) includes, among other items, unrealized gains and losses on the changes in fair value of investments and foreign currency translation adjustments for entities not using the U.S. Dollar as their functional currency. These components are added, net of their related tax effect, to the reported net income (loss) to arrive at comprehensive income (loss). The components of accumulated other comprehensive income at December 31, 2014, on the Company’s consolidated balance sheet was comprised of the net unrealized net holding gains on the Company’s investments in marketable securities and foreign currency translation adjustments related to the consolidation of the Company’s variable interest entity which does not use the U.S. Dollar as its function currency. There was no similar accumulated other comprehensive income or loss components at December 31, 2013 and 2012. See Note 4 for further detail of the unrealized holdings gains and losses on the Company’s investments in marketable securities and Note 9 for further detail of the Company’s variable interest entity.
	Concentration Risk
	Credit Risk. Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain safety and liquidity. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, restricted cash and marketable securities.
	Manufacturing. The Company depends on an outsourced manufacturing strategy for its product candidates. It currently has a single source of supply for its drugs substance and has a single manufacturer for its drug product. If the Company’s third-party manufacturers are unable to manufacture its products, or if its suppliers or third-party manufacturers decide they no longer want to manufacture its products, the Company may need to find alternative manufacturing facilities, which would be time-consuming and significantly impact its ability to develop, obtain regulatory approval for or market our products.
	Net Loss per Share
	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, unvested restricted common stock subject to repurchase, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for all periods presented.
	The actual net loss per shares amounts for the years presented were computed based on the weighted average shares of common stock outstanding during the respective periods and includes the effect of the (1) 8,050,000 common shares issues pursuant to the initial public offering in February 2014; and (2) 3,622,500 common shares issued pursuant to the follow-on offering in the third quarter of 2014. As a result of the issuance of these common shares, there is a lack of comparability in the basic and diluted net loss per share amounts for the periods presented. See Note 8 for further discussion.
	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		Year Ended December 31,
		2014		2013		2012
	Convertible preferred stock		—		14,937,836		9,109,868
	Warrants to purchase convertible preferred stock		—		859,743		824,944
	Warrants to purchase common stock		547,089		—		—
	Common stock options		1,992,012		986,111		512,228
	Common stock subject to repurchase		624,710		955,555		—
		3,163,811		17,739,245		10,447,040
Income Taxes
Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. A valuation allowance is recorded when it is more likely than not that some, or all, of the deferred tax assets will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies.
The Company assesses its income tax positions and record tax benefits for all years subject to examination based upon its evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, the Company has recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the consolidated financial statements.
Recent Accounting Pronouncements
In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, Development State Entities, which eliminates the financial reporting distinction between development stage entities and other reporting entities, thereby eliminating the requirements to present inception-to-date information in the statements of operations and stockholders’ equity and cash flow, or label the financial statements as those of a development stage entity. The Company has elected to early adopt this guidance, as permitted, for its financial statements for the year ended December 31, 2014, and therefore has no longer labeled its consolidated financial statements as those of a development stage entity or included any inception-to-date information.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 requires management to perform interim and annual assessments on whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year of the date the financial statements are issued. If such conditions or events exist, certain disclosures are required. ASU No. 2014-15 is effective prospectively for fiscal years beginning after beginning December 15, 2016 and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of the pending adoption of ASU No. 2014-15 on its consolidated financial statements and related disclosures.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements
	The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
	As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The carrying amounts of the Company’s prepaid expenses, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short nature of these instruments. Further, based upon borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its note payable approximates its carrying value. No transfers between levels have occurred during the periods presented.
	Assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 and 2013, are as follows (in thousands):
					Fair Value Measurements Using
		Balance as of December 31, 2014			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Money market funds(1)	$	20,371		$	20,371	$	—	$	—
	Commercial paper		26,325			—		26,325		—
	Corporate debt securities(2)		93,433			—		93,433		—
	Total	$	140,129		$	20,371	$	119,758	$	—
	-1	Included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.
	-2	Corporate debt securities purchased within three months of maturity valued at $4,610 is included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.
					Fair Value Measurements Using
		Balance as of December 31, 2013			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Series C preferred stock warrants	$	1,165		$	—	$	—	$	1,165
	Series D preferred stock warrants		2,330			—		—		2,330
	Series E preferred stock warrants		480			—		—		480
	Total	$	3,975		$	—	$	—	$	3,975
	The Company’s investments in money market funds are valued based on publicly available quoted market prices for identical securities as of  December 31, 2014. The Company determines the fair value of commercial paper and corporate bonds with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at December 31, 2014.
	As discussed in Note 2 above, all of the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock in connection with the IPO and are accounted for as equity from the conversion date forward. Prior to the conversion, the Company estimated the fair value of convertible preferred stock warrants at the time of issuance and subsequent remeasurements using the Black-Scholes option-pricing model at each reporting date, using the following inputs: the risk-free interest rates; the expected dividend rates; the remaining expected life of the warrants; and the expected volatility of the price of the underlying common stock.
	The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrant liability as of February 10, 2014, the conversion date, and December 31, 2013:
		February 10,			December 31,
		2014			2013
	Risk-free interest rate	0.07%-2.64%			0.07%-3.04%
	Expected dividend yield		0%			0%
	Expected volatility	69.66%-87.51%			66.49%-85.10%
	Expected term (in years)	0.29-9.89			0.39-9.99
	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Warrant
		Liability
	Balance at January 1, 2013	$	1,556
	Issuance of warrants		606
	Exercise of tranche rights		(118	)
	Change in fair value(1)		1,931
	Balance at December 31, 2013		3,975
	Change in fair value(1)		3,634
	Reclassification of warrants(2)		(7,609	)
	Balance as of December 31, 2014	$	—
	-1	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.
	-2	In connection with the completion of the Company’s IPO in February 2014, the Company reclassified the warranty liability to stockholders’ equity as the warrants met the definition of an equity instrument under derivative accounting guidance.

Investments_in_Marketable_Secu

Investments in Marketable Securities	12 Months Ended
	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Investments in Marketable Securities	4. Investments in Marketable Securities
	The Company had no investments in marketable securities at December 31, 2013. Investments classified as available-for-sale at December 31, 2014, consisted of the following (in thousands):
		Maturity	Amortized		Gross		Gross			Aggregate
		(in years)	Cost		Unrealized		Unrealized			Estimated
					Gains		Losses			Fair Value
	Marketable Securities:
	Corporate debt securities(1)	1 year or less	$	93,470	$	2	$	(39	)	$	93,433
	Commercial paper(1)	1 year or less		21,673		42		—			21,715
	Total available-for-sale securities		$	115,143	$	44	$	(39	)	$	115,148
	(1)There were no securities scheduled to mature outside of one year at December 31, 2014.
	During the year ended December 31, 2014, the Company realized an immaterial gain on the sale of an available-for-sale security that had been downgraded and fell outside of the Company’s investment policy. No further gains or losses were realized on sales or maturities of available-for-sale securities for the year ended December 31, 2014. Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2014, there were 23 securities in unrealized loss positions. These securities have not been in a continuous unrealized loss position for more than 12 months. Further, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

Other_Balance_Sheet_Items

Other Balance Sheet Items	12 Months Ended
	Dec. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Items	5. Other Balance Sheet Items
	Prepaid and other current assets consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Prepaid clinical trial costs	$	4,568		$	—
	Prepaid insurance		203			72
	Interest receivable		567			—
	Prepaid other and other current assets		373			170
	Total	$	5,711		$	242
	Property and equipment consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Computer equipment and software	$	137		$	45
	Leasehold improvements		46			5
	Furniture and fixtures		43			16
	Office equipment		23			12
	Machinery and equipment		4			4
			253			82
	Less accumulated depreciation		(76	)		(56	)
	Total	$	177		$	26
	Accrued liabilities consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Clinical trial accruals	$	1,168		$	565
	Accrued personnel costs		2,679			475
	Manufacturing cost accrual		212			772
	Other accrued expenses		604			315
	Total	$	4,663		$	2,127

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	6. Long-Term Debt
	In December 2013, the Company entered into a term loan facility with Oxford Finance LLC and its assignees. The loan facility provides funding for an aggregate principal amount of $15,000,000, which was funded at closing, is collateralized by the Company’s assets excluding intellectual property, bears a fixed interest rate of 8.99% per year and matures on January 1, 2018. The original terms of the loan facility provided that the Company would make interest-only payments for 12 months beginning on February 1, 2014 and equal monthly principal and interest payments over 36 months thereafter. In accordance with the terms of the loan facility, upon the completion of the Company’s IPO in February 2014, the interest-only period was extended by an additional 6 months to 18 months with equal monthly principal and interest payments over 30 months thereafter (reduced from 36 months). In December 2014, the Company amended the loan facility to extend the interest-only payment period and is currently subject to interest-only payments through January 1, 2016, to be followed by 24 equal monthly principal and interest payments. However, if the Company completes an NDA submission of SD-809 for chorea associated with Huntington’s disease by June 30, 2015, and are otherwise in compliance with the loan facility, the interest-only period will be extended to 30 months, followed by 18 equal monthly principal and interest payments. Upon repayment of the term loan, the Company is required to make a final payment to the lenders equal to 3% of the original principal balance of the loan which is being accrued over the term of the loan. In connection with the loan facility, the Company issued warrants to the lender and incurred debt issuance costs of $100,000. The fair value of the warrants, recorded as a discount to the debt and the debt issuance costs recorded as a deferred asset, are being amortized to interest expense over the expected life of the loan agreement. See Note 7 below for further discussion of the warrants.
	The Company is permitted to make voluntary prepayments of the term loan with a prepayment fee equal to (i) 3% of the term loan prepaid during the first 12 months, (ii) 2% of the term loan prepaid in months 13-24 and (iii) 1% of the term loan prepaid thereafter. The Company is required to make mandatory prepayments of the outstanding term loan upon the acceleration by the lenders of such term loan following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of the prepayment. The Company is also subject to certain non-financial covenants. As of December 31, 2014, the Company has not experienced any events of default and was in compliance with all covenants under the loan facility.
	Future minimum payments under the term loan are as follows (in thousands):
	Year Ending December 31,
	2015	$	1,350
	2016		7,650
	2017		8,223
	2018		1,135
	Total future minimum payments		18,358
	Less amounts representing interest and fees		(2,908	)
	Less end of term payment		(450	)
	Gross balance of long-term debt		15,000
	Less unamortized discount		(405	)
	Total present value of long-term debt		14,595
	Less current portion		—
	Long-term portion	$	14,595

Convertible_Preferred_Stock_Wa

Convertible Preferred Stock Warrants	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Convertible Preferred Stock Warrants	7. Convertible Preferred Stock Warrants
	Prior to the completion of the Company’s IPO in February 2014, the Company accounted for the warrants it had previously issued for the purchase of the Company’s convertible preferred stock in connection with its 2009, 2010, 2011 and 2012 convertible notes and its January and December 2013 credit facilities, as liabilities based on the “deemed liquidation” terms of the convertible preferred stock. Upon consummation of the Company’s IPO in February 2014, all of the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock at a 1-to-1 ratio, adjusted for the January 16, 2014 reverse stock split, and the Company reclassified the warrant liability to stockholders’ equity as the warrants met the definition of an equity instrument under the derivatives accounting guidance.
	The following table summarizes the shares subject to outstanding warrants and the corresponding exercise price as of December 31, 2014 and 2013:
		Number of Shares Outstanding
		December 31,		December 31,		Exercise Price		Expiration Date
		2014		2013
	May 2009 Series C Warrants		—		507,910	$	0.862	22-May-14
	October 2009 Series C Warrants		—		464,035	$	0.862	9-Oct-14
	January 2010 Series C Warrants		—		457,285	$	0.862	8-Jan-15
	December 2011 Series D Warrants		—		654,292	$	0.862	15-Dec-16
	April 2012 Series D Warrants		—		654,291	$	0.862	20-Apr-07
	July 2012 Series D Warrants		—		348,027	$	0.862	18-Jul-17
	August 2012 Series D Warrants		—		348,027	$	0.862	28-Aug-17
	January 2013 Series D Warrants		—		174,014	$	0.862	9-Jan-23
	December 2013 Series E Warrants		—		261,020	$	1.724	27-Dec-23
	Common Stock Warrants		547,089		—	$	3.879
	Total		547,089		3,868,901
	Series C and D Preferred Stock Warrants
	In connection with convertible notes that were fully converted to preferred stock prior to December 31, 2013, the Company issued warrants to note holders for the purchase of shares of Series C Preferred Stock (“Series C warrants”) and Series D Preferred Stock (“Series D warrants”). At December 31, 2013 there were Series C warrants outstanding for the purchase of an aggregate of 1,429,230 shares of Series C Preferred Stock and Series D warrants, issued through August 2012, outstanding for the purchase of an aggregate of 2,004,637 shares of Series D Preferred Stock. Upon completion of the Company’s IPO in February 2014, these warrants converted into warrants to purchase an aggregate of 763,073 shares of the Company’s common stock at an exercise price of $3.879 per share. In May 2014, warrants subject to an aggregate of 112,867 shares of common stock were exercised, a portion of which were exercised through cashless net exercises, and resulted in a total issuance of 100,467 shares of common stock. In October 2014, warrants subject to an aggregate of 103,117 shares of common stock were exercised through cashless net exercises, resulting in a total issuance of 86,237shares of common stock. As of December 31, 2014, there were warrants to purchase an aggregate of 547,089 shares of the Company common stock outstanding.
	January and December 2013 Preferred Stock Warrants
	In connection with a January 2013 credit facility which was paid in full prior to December 31, 2013, the Company issued a fully exercisable warrant for the purchase of 174,014 shares of Series D Preferred Stock at $0.862 per share, expiring January 9, 2023. Upon completion of the Company’s IPO in February 2014, the warrant converted into a warrant for the purchase of 38,669 shares of the Company’s common stock at an exercise price of $3.879 per share. In February 2014, the warrant was fully exercised through a cashless net exercise and the Company issued a net of 33,469 shares of common stock.
	In connection with the funding of the December 2013 term loan, the Company issued fully exercisable warrants to the lender to purchase an aggregate of 261,020 shares of Series E Preferred Stock at a purchase price of $1.724 per share, expiring December 27, 2023. The warrants were valued at $480,000 at issuance and were recorded as a loan discount, utilizing the Black-Scholes option-pricing model and are being amortized to interest expense over the expected term of the loan agreement. Upon completion of the Company’s IPO in February 2014, the warrants converted into warrants to purchase an aggregate of 58,001 shares of the Company’s common stock at an exercise price of $7.758 per share. In December 2014, the warrant was fully exercised through a cashless net exercise and the Company issued a net of 49,721 shares of common stock

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity
	Authorized Shares
	In connection with the completion of the Company’s IPO in February 2014, the Company amended its Certificate of Incorporation to authorize 10,000,000 shares of preferred stock, par value $0.0001 per share, and 200,000,000 shares of common stock, par value $0.0001 per share.
	Public Offerings and Related Transactions
	On February 10, 2014, the Company completed its IPO selling 8,050,000 shares of common stock at $12.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $86,658,000.
	In addition, each of the following occurred in connection with the completion of the Company’s IPO on February 10, 2014:
	·	the conversion of all outstanding shares of convertible preferred stock into 14,397,836 shares of the Company’s common stock; and
	·	the conversion of warrants to purchase 3,868,901 shares of convertible preferred stock into warrants to purchase 859,743 shares of the Company’s common stock and the resultant reclassification of the warrant liability to additional paid-in capital.
	In July 2014, the Company completed a follow-on offering whereby it issued an aggregate 3,622,500 shares of common stock at $19.25 per share. Proceeds from the follow-on offering, net of underwriting discounts, commissions and offering expenses, were $64,973,000.
	Convertible Preferred Stock
	Prior to its conversion in the IPO, the Company’s convertible preferred stock was classified on the Company’s balance sheets as temporary equity, instead of stockholders’ (deficit) equity, in accordance with authoritative guidance for the classification and measurement of redeemable securities. Upon certain change in control events that are outside of the Company’s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.
	Equity Awards
	In January 2014, the Company’s board of directors and stockholders approved and adopted the 2014 Equity Incentive Plan (the “2014 Plan”) in connection with the Company’s initial public offering and the 2014 Plan became effective in February 2014. Upon adoption of the 2014 Plan, the Company restricted future grants from its 2010 Equity Incentive Plan (the “2010 Plan”).
	The 2014 Plan initially reserved 1,110,000 new shares, plus an amount not to exceed 3,059,326 shares which represented (1) the number of shares reserved for issuance under the 2010 Plan at the time the 2014 Plan became effective and (2) any shares subject to outstanding stock options or other stock awards that would have otherwise returned to the 2010 plan (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1st of each year, from January 1, 2015 continuing through January 1, 2024, by 4% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors.
	The 2014 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSUs”), performance-based stock awards, and other forms of equity compensation, which we refer to collectively as stock awards, all of which may be granted to employees, including officers, non-employee directors and consultants of us and our affiliates. Additionally, the 2014 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees and the maximum number of shares that may be issued upon the exercise of ISOs under the 2014 Plan is 8,318,652 shares.
	The Company issues new shares of common stock upon the exercise of stock options, award of restricted stock awards and vesting of RSUs and performance-based awards, if any.
	As of December 31, 2014, the Company has issued only stock options under the 2014 Plan and both stock options and restricted shares under the 2010 Plan. The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans at December 31, 2014:
							Outstanding
									Nonvested
		Authorized			Available		Options		Restricted Shares
	2010 Equity Incentive Plan		2,744,764			—		1,361,345		608,968
	2014 Equity Incentive Plan		1,652,948			1,022,281		630,667		—
			4,397,712			1,022,281		1,992,012		608,968
	Not included in the outstanding option balance above are 15,742 shares pursuant to stock options that were early exercised and subject to repurchase under the 2010 Plan at December 31, 2014.
	Stock Options.  Stock options granted under the 2014 Plan expire no later than 10 years from the date of grant and generally vest over a four-year period with vesting generally occurring at a rate of 25% at the end of the first year, and thereafter in 36 equal monthly installments. However grants to the Company’s board members vest over a period of one-year. The exercise price of the Company’s stock options generally cannot be less than 100% of the fair value of the Company’s common stock on the date of grant. Further the exercise price of any ISOs granted to a 10% stockholder may not be less than 110% of the fair value of the Company’s common stock on the date of grant.
	The following table summarizes the Company’s stock option activity as of December 31, 2014, and changes for the year then ended:
							Weighted-
					Weighted-		Average
					Average		Remaining		Aggregate
					Exercise		Contractual		Intrinsic
		Shares			Price		Life (in Years)		Value
	Options outstanding at beginning of period		986,111		$	0.73
	Granted		1,278,646		$	15.87
	Exercised		(254,717	)	$	0.89
	Cancelled		(18,028	)	$	14.66
	Options outstanding at end of period		1,992,012		$	10.3		8.89	$	84,027,000
	Options exercisable at end of period		259,974		$	1.5		8.07	$	13,253,800
	The aggregate intrinsic value of options exercised during 2014 and 2013 was $6,415,000 and $8,000, respectively. There were no options exercised during 2012. During 2014 the Company received $227,000, upon the exercise of stock options in satisfaction of the exercise price.
	Restricted Shares.  The Company has granted restricted shares to a limited number of individuals subject to service conditions. The Company maintains a repurchase right where shares of restricted common stock are released from such repurchase right over a period of time subject to continued service by the recipient. No such awards were granted in 2014 and 2012, however the Company granted 1,100,793 restricted shares in 2013, of which 491,825 restricted shares had vested and 608,968 remained unvested as of December 31, 2014. The following table further summarizes the Company’s restricted share activity as of December 31, 2014, and changes for the year then ended:
					Weighted-
					Average		Aggregate
					Grant Date		Intrinsic
		Shares			Fair Value		Value
	Nonvested restricted shares at beginning of period		933,333		$	0.54
	Vested		(324,365	)	$	0.54
	Nonvested restricted shares end of period		608,968		$	0.54	$	31,905,000
	The nonvested restricted shares and shares purchased by employees subject to early exercise provisions are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to restricted shares and stock options grants is recorded as a liability on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. The aggregate intrinsic value of restricted shares vested during 2014, at the vesting date, was $6,362,000. The intrinsic value of restricted shares vested during 2013 was less than $1,000. As of December 31, 2014 and 2013, the Company had liabilities on its balance sheet of $40,000 and $62,000, respectively, for restricted shares subject to repurchase rights.
	Employee Stock Purchase Plan
	On January 15, 2014, the Company’s board of directors and stockholders approved and adopted the ESPP. The ESPP became effective and the first purchase period began upon the execution and delivery of the underwriting agreement for the IPO on February 4, 2014. The ESPP permits eligible employees to make payroll deductions to purchase up to $25,000 of the Company’s common stock in each calendar year on regularly scheduled purchase dates at a discount. Offering periods under the ESPP are not more than 27 months in duration and shares are purchased at 85% of the lower of the closing price for the Company’s common stock on the first day of the offering period or the date of purchase. The ESPP initially authorized the issuance of 300,000 shares of the Company’s common stock under the ESPP. The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year, from January 1, 2015, continuing through January 1, 2024, by an amount equal to the lessor of (a) 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, (b) 530,000 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b).
	The following table further summarizes the Company’s ESPP activity as of December 31, 2014, and changes for the year then ended:
		Shares
	Shares authorized for issuance under the 2014 ESPP at beginning of period		—
	Shares authorized in February 2014		300,000
	May purchase		(7,895	)
	November purchase		(16,720	)
	Shares authorized for issuance under the 2014 ESPP at end of period		275,385
	Total common stock reserved for issuance under our equity plans, ESPP and pursuant to outstanding warrants as of December 31, 2014, was as follows:
		Shares
	Warrants to purchase common stock outstanding		547,089
	Stock options outstanding		1,992,012
	Early exercise of stock options subject to repurchase		15,742
	Nonvested restricted shares subject to repurchase		608,968
	Equity plan shares authorized for future awards		1,022,281
	ESPP shares authorized for issuance		275,385
		4,461,477

Variable_Interest_Entity

Variable Interest Entity	12 Months Ended
	Dec. 31, 2014
Variable Interest Entity Measure Of Activity [Abstract]
Variable Interest Entity	9. Variable Interest Entity
	On July 1, 2014, the Company entered into a License and Joint Development Agreement (the “Agreement”) with an early development stage company (the “Development Partner”), Imphar AG, for certain intellectual property rights related to deuterated oral small molecule compounds for the treatment of certain neurological disorders that are distinct from and not related to our late stage SD-809 program. These compounds are in the early stage of development and the Company plans to advance the program in collaboration with its partner through an agreed upon development plan. Pursuant to the Agreement, the parties are to share equally all development costs to obtain regulatory approval in the United States and Europe and each party has equal representation on both a joint steering and joint development committee. If the Development Partner fails to timely fund its share of the development plan costs, the Company has the option to provide additional funding and in return the Company will be entitled to additional potential future commercialization rights, revenues and royalty payments.
	At the time the Agreement was entered, the Company determined it held a variable interest in the Development Partner’s intellectual property assets and the related potential future product candidates these assets may produce. In the absence of other significant development programs at the Development Partner, the Development Partner was considered a VIE. Although the Company does not have an equity investment in the VIE, it was determined to be the primary beneficiary for the VIE as the party controlling its principal activities. Therefore the VIE is subject to consolidation and the Company has consolidated the financial statements of the Company and the VIE since inception of the agreement on July 1, 2014.
	At the inception of the Agreement, the VIE was determined not to be a business and the identifiable assets, assumed liabilities and non-controlling interest of the VIE were recorded at their preliminary estimated fair value upon the initial consolidation of the VIE, including the intellectual property assets. However, the intellectual property assets represented in-process research and development and did not qualify for capitalization as they had no alternative future use. As a result, the Company recorded a loss upon consolidation in the third quarter of 2014 of $4,781,000, which was subsequently reduced by $512,000 in December 2014 based on the completion of a valuation analysis of the estimated fair value of the intellectual property assets, resulting in a net loss upon consolidation of $4,269,000for the year ended December 31, 2014. As of December 31, 2014 the Company has recorded $3,784,000 as the fair value of the non-controlling interest in connection with the consolidation of the VIE.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies
	Lease
	In June 2011, the Company entered into a noncancelable operating lease for corporate office space, as amended (the “Lease”). In June 2012, the Company amended the Lease for additional square footage (the “First Amendment”), which term was extended through a second amendment (the “Second Amendment”) in November 2012. In February 2014, the Company entered into a third amendment to its Lease (the “Third Amendment”) and a lease assignment (the “Lease Assignment”) to provide for additional space.
	In July 2014, the Company entered into the Fourth Amendment to the Lease (the “Fourth Amendment”), pursuant to which the Company began leasing new office space in September 2014 that is serving as its corporate headquarters. All office space previously occupied pursuant to the Lease, was replaced by the new office space pursuant to the Fourth Amendment. The Fourth Amendment further provided for additional office space that became available in January 2015. In November 2014, the Company entered into the Fifth Amendment to the Lease (the “Fifth Amendment”) which provided for further expansion space. The Lease will expire in March 2020, and the Company has an option to extend the term for either five additional years or one additional year. Further, the Company has a one-time right to terminate and cancel the Lease, subject to conditions and termination dates.
	The Company is subject to charges for common area maintenance and other costs pursuant to the Lease, and the Lease provides for abatement of rent during certain periods and escalating rent payments throughout the term of the Lease. Rent expense is being recorded on straight line basis over the life of the Lease and the difference between the rent expense and rent paid is being recorded as deferred rent.
	Future minimum payments as of December 31, 2014, pursuant to the Fourth and Fifth Amendments, are as follows (in thousands):
	Year Ending December 31,
	2015	$	860
	2016		1,140
	2017		1,175
	2018		1,211
	2019		1,246
	2020		319
	Total minimum lease payments	$	5,951
	Patent Assignment Agreement
	In September 2011, the Company entered into a patent assignment agreement with Concert Pharmaceuticals, Inc. (“Concert”) pursuant to which Concert assigned to the Company a U.S. patent application relating to deuterated pirfenidone. Under the terms of the agreement, Concert is eligible to receive certain royalty payments (the “Royalty Payments”), equal to a percentage in the low single digits of net sales in the United States invoiced by the Company, or any of its affiliates, with respect to certain pharmaceutical products containing deuterated pirfenidone. If the Company sells to another party all of its U.S. rights to certain deuterated pirfenidone products, or if the Company grants to another party a license to sell certain deuterated pirfenidone products in the United States, Concert will receive an amount (the “Sublicense/Sale Payments”), equal to a percentage in the teens of any proceeds the Company receives therefrom that are attributable to the rights to such deuterated pirfenidone products in the United States. If the Company is acquired in a change in control transaction at any time while the Company, or any of its affiliates, own certain patents or patent applications related to deuterated pirfenidone, Concert will receive 1.44% of any proceeds the Company receives in such transaction. Such payment is to be applied as a credit to any future Royalty Payments and Sublicense/Sale Payments that may be due to Concert under the agreement. The agreement expires upon the earlier to occur of (1) receipt by Concert of the final Sublicense/Sale Payment arising from (a) the sale of the Company’s U.S. rights to certain deuterated pirfenidone products or (b) the Company’s grant of an exclusive license to sell certain deuterated pirfenidone products in the United States in all indications and fields, or (2) the expiration of the last claim owned by the Company or any of its affiliates in certain patents or patent applications related to deuterated pirfenidone.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	11.Employee Benefit Plan
	The Company maintains a defined contribution employee retirement plan for our employees under the provisions of Section 401(k) of the Internal Revenue Code. Employees may contribute up to 90% of his or her compensation up to the maximum annual amount prescribed by the Internal Revenue Service. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. During 2014, 2013 and 2012, the Company elected not to make any contributions to the plan.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes
	The Company is subject to taxation in the U.S. and various state jurisdictions. The Company’s tax years for 2001 and forward are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrued interest or penalties related to income tax matters in the Company’s consolidated balance sheets at December 31, 2014 and 2013, respectively, and has recognized no interest and/or penalties in the Company’s consolidated statements of operations for the years ended December 31, 2014, 2013 and 2012.
	Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event of a cumulative change in ownership of more than 50% within a three-year period. The Company has not completed the analysis regarding this limitation and therefore has removed the (1) deferred tax assets for net operating losses of approximately $34,100,000 and (2) research and development credits of approximately $6,400,000 generated through 2014 from its deferred tax asset schedule and recorded a corresponding decrease to its valuation allowance. When this analysis is completed, the Company plans to update its deferred tax asset and valuation allowance accordingly. Until such analysis is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an uncertain tax benefit. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact the Company’s effective tax rate.
	A valuation allowance has been established as realization of such deferred tax assets has not met the more likely than not threshold requirement. Other significant components of the Company’s net deferred tax assets for federal and state income taxes at December 31, 2014 and 2013, are shown below (in thousands):
		As of  December 31,
		2014			2013
	Deferred tax assets:
	Capitalized research and development	$	6,093		$	7,409
	Accrued compensation		999			39
	Stock-based compensation		917			21
	Other, net		419			48
			8,428			7,517
	Valuation allowance for deferred tax assets		(8,428	)		(7,517	)
	Net deferred tax assets	$	—		$	—
	A reconciliation of the Company’s effective tax rate and federal statutory rate is as follows:
		As of  December 31,
		2014		2013	2012
	Federal income taxes	34.00%		34.00%	34.00%
	State income taxes	4.60%		4.80%	5.10%
	Research and development credits	4.40%		3.30%	0.60%
	Change in valuation allowance	-1.50%		-17.40%	-24.20%
	Fair value adjustments	-2.20%		-5.00%	-0.40%
	Nondeductible interest	—		—	-3.30%
	Removal of net operating loss and research and development tax credits	-38.10%		-18.90%	-11.40%
	Nondeductible expenses and other	-1.20%		-0.80%	-0.40%
		0.00%		0.00%	0.00%
	At December 31, 2014, the Company had federal and state net operating losses of approximately $91,200,000 and $94,100,000, respectively. The federal net operating loss carryforwards will begin to expire in 2021 unless previously utilized, and the state net operating loss carryforwards will continue to expire in 2015. The Company also had federal and state research and development tax credit carryforwards of approximately $5,200,000 and $1,800,000, respectively. The federal research and development tax credit carryforwards will begin expiring in 2021, unless previously utilized. The state research and development tax credits carryforwards do not expire.
	Included in the net operating loss carryforwards at December 31, 2014, is approximately $6,000,000 of losses attributable to excess stock option deductions. Under current accounting guidance concerning when tax benefits related to excess stock option deductions can be credited to paid in capital, the related valuation allowance cannot be reversed, even if the facts and circumstances indicate that it is more likely than not that the deferred tax asset can be realized. The valuation allowance will only be reversed as the related deferred tax asset is applied to reduce taxes payable.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	13.Selected Quarterly Financial Data (Unaudited)
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Selected quarterly financial data for years ended December 31, 2014 and 2013, are as follows (in thousands, except share and per share amounts):
		Fiscal Year 2014 Quarters
		1st(3)			2nd			3rd(4)			4th(5)			TOTAL
	Operating loss	$	(6,106	)	$	(10,039	)	$	(13,909	)	$	(20,202	)	$	(50,256	)
	Net loss	$	(10,123	)	$	(10,385	)	$	(19,025	)	$	(20,002	)	$	(59,535	)
	Net income attributed to noncontrolling interest	$	—		$	—		$	13		$	26		$	39
	Net loss attributable to Auspex shareholders	$	(10,123	)	$	(10,385	)	$	(19,038	)	$	(20,028	)	$	(59,574	)
	Basic and diluted net loss per share(1)(2)	$	(0.81	)	$	(0.45	)	$	(0.73	)	$	(0.74	)	$	(2.68	)
		Fiscal Year 2013 Quarters
		1st			2nd			3rd			4th			TOTAL
	Operating loss	$	(2,630	)	$	(2,817	)	$	(2,837	)	$	(4,908	)	$	(13,192	)
	Net loss	$	(2,305	)	$	(2,889	)	$	(2,846	)	$	(7,589	)	$	(15,629	)
	Net income attributed to noncontrolling interest	$	—		$	—		$	—		$	—		$	—
	Net loss attributable to Auspex shareholders	$	(2,305	)	$	(2,889	)	$	(2,846	)	$	(7,589	)	$	(15,629	)
	Basic and diluted net loss per share(1)(2)	$	(17,462	)	$	(21,886	)	$	(21,561	)	$	(46	)	$	(371	)
	-1	Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year.
	-2	In the first quarter of 2014, the Company issued 8,050,000 shares of common stock as part of its initial public offering. Further, the Company issued an additional 3,622,500 shares of common stock pursuant to a follow-on offering in July 2014. As a result, there is a lack of comparability in the basic and diluted net loss per share amount for the periods presented.
	-3	During the first quarter of 2014, in conjunction with the Company’s initial public offering, the Company recognized a change in the fair value of its convertible preferred stock warrants, resulting in a loss of $3,634.
	-4	During the third quarter of 2014, the Company recognized a $4,781 loss on the initial consolidation of the assets and liabilities of a VIE it began consolidating during the quarter.
	-5	During the fourth quarter of 2014, the Company recorded an adjustment to the loss on the initial consolidation of the VIE, reducing the loss by $512.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events
	Share Purchase Agreement
	On January 11, 2015, the Company entered into a share purchase agreement to acquire the remaining rights to SD-1077, and related intellectual property, through the acquisition of Imphar AG. Imphar AG had previously granted Auspex exclusive U.S. and select worldwide rights and retained European and additional worldwide rights, all of which were transferred to Auspex upon the closing of the transaction on January 31, 2015.
	Sales of Common Stock
	In January 2015, the Company completed a public follow-on offering whereby it issued an aggregate 3,600,000 shares of common stock at $56.50 per share. Proceeds from the follow-on offering, net of underwriting discounts, commissions and offering expenses, were approximately $190,496,000. The public offering also included the sale of 1,000,000 shares of common stock by existing stockholders of Auspex, for total shares sold of 4,600,000

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles and with the rules and regulations of the Securities and Exchange Commission (“SEC”) and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of convertible preferred stock warrants, equity awards and clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Basis of Consolidation	Basis of Consolidation
	The Company’s consolidated financial statements include the financial statements of the Company and a variable interest entity (“VIE”) for which the Company has been determined to be the primary beneficiary (see Note 9 for further discussion). All intercompany accounts between the Company and the VIE have been eliminated in consolidation. The Company will continue to assess its relationship with the VIE on an ongoing basis as circumstances requiring consolidation may change.
Segment Reporting	Segment Reporting
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Reverse Stock Split	Reverse Stock Split
	On January 16, 2014, the Company effected a 1-for-4.5 reverse stock split of the Company’s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements have been retroactively adjusted to reflect the January 2014 reverse stock split for all periods presented.
Cash, Cash Equivalents and Marketable Securities	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash and highly liquid securities with maturities at the date of acquisition of ninety days or less. Investments with maturities at the date of acquisition of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, marketable securities, restricted cash, trade payables, accrued liabilities and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, trade payables and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based upon the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of long-term debt approximates its carrying value. The fair value of marketable securities is based upon market prices quoted on the last day of the fiscal period or a fair value representing the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. See Note 3 for further discussion of fair value measurements.
Convertible Preferred Stock Warrants	Convertible Preferred Stock Warrants
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company’s convertible preferred stock warrants were classified as liabilities, and the Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. In connection with the completion of the Company’s initial public offering (“IPO”) in February 2014, all the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As a result of the IPO and warrant conversion, the Company reclassified the warrant liability as stockholders’ equity because the converted warrants met the definition of an equity instrument under derivative accounting guidance. The Company performed the final remeasurement of the warrant liability as of the IPO date in February 2014, and recorded the $3,634,000 change in fair value as other income (expense) at that time.
Stock-Based Compensation Expense	Stock-Based Compensation Expense
	The Company has stock-based compensation plans and an employee stock purchase plan, which are described in Note 8. As of December 31, 2014, the Company had issued both stock option awards and restricted stock units under its stock-based compensation plans and permitted eligible employees to participate in an employee stock purchase plan (“ESPP”) whereby shares of the Company’s common stock may be purchased at a discount. The Company accounts for stock option grants and participation in the ESPP using the Black-Scholes option pricing model.  Restricted stock awards are valued based on their fair market value at the time of grant. Further discussion of the expense related to these programs is provided below:
	Stock option awards. Stock options are valued using the Black-Scholes option pricing model. The Company values option awards on the date of grant or, if the awards are classified as liability awards, it revalues the awards each reporting period using this model until the awards are subsequently classified as equity awards, or otherwise vest or are cancelled. The Black-Scholes option pricing model involves a number of estimates, including the expected lives of stock options, the Company’s anticipated stock volatility and interest rates. The following table summarizes the weighted-average estimates the Company used in the Black-Scholes option pricing model for the years ended December 31, 2014, 2013 and 2012, to determine the grant-date fair value of stock options granted during each period for its stock option awards:
		Year Ended December 31,
		2014		2013		2012
	Risk free interest rate		1.40%		1.50%		1.00%
	Expected life in years	6.2 years		6.1 years		6.0 years
	Expected dividend yield		0.00%		0.00%		0.00%
	Expected volatility		87.20%		82.60%		94.30%
	The Company determines its risk-free interest rate assumption based on the U.S. Treasury yield for obligations with contractual lives similar to the expected lives of the Company’s share-based payment awards being valued. The weighted-average expected life of options is calculated using the simplified method, as prescribed by the SEC, due to the lack of relevant historical exercise data. Due to the Company’s limited historical stock price volatility data, the estimated volatility is determined by incorporating the historical stock price volatility of comparable companies whose shares prices are publicly available. The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future. Forfeitures are estimated based upon the historical and anticipated future experience.
	Based upon these assumptions, the Company has estimated the per share weighted-average grant date fair value of its options granted for the years ended December 31, 2014, 2013 and 2012 at $11.54, $0.55 and $0.63, respectively.
	Restricted stock awards. Restricted stock awards are valued based on the fair market value of the Company’s stock on the date of grant. The weighted-average grant date fair value of the RSUs granted in 2013 was $0.54. There were no restricted stock awards granted in 2014 or 2012.
	Employee Stock Purchase Plan. In 2014 the Company began permitting eligible employees to purchase shares of the Company’s common stock at a discount to the fair market value at semi-annual intervals. In determining the value of shares issued under the ESPP, the Company uses the Black-Scholes option pricing model and values the contributions at each purchase interval or when contributions are modified. The Black-Scholes inputs are determined in the same manner as for stock options and the weighted-average inputs used for the ESPP for the year ended December 31, 2014, were as follows:
		Year Ended December 31, 2014
	Risk free interest rate		0.20%
	Expected life in years	1.3 years
	Expected dividend yield		0.00%
	Expected volatility		82.00%
	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options, restricted stock and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Year Ended December 31,
		2014		2013		2012
	Research and development	$	1,832	$	89	$	43
	General and administrative		1,975		211		39
	Total stock-based compensation expense	$	3,807	$	300	$	82
	The total unrecognized stock-based compensation expense related to unvested stock options and restricted shares not yet vested at December 31, 2014, was approximately $13,848,000 to be recognized over a weighted-average period of approximately 39 months. The total unrecognized stock-based compensation expense related to the ESPP at December 31, 2014, was approximately $253,000, which is expected to be recognized over a weighted-average period of approximately 7 months.
Research and Development	Research and Development
	The Company’s research and development expenses consist primarily of costs associated with clinical trials managed by the Company’s contract research organizations (“CROs”), salaries and related employee benefits, and costs associated with non-clinical activities, such as regulatory, drug development of product candidates, and pre-commercialization manufacturing expenses. The Company uses external service providers and vendors to conduct clinical trials, to manufacture product candidates to be used in clinical trials and to provide various other research and development related products and services. The Company accounts for research and development expenditures as incurred and accrues expenses based upon estimates of work performed, patient enrollment and experience with similar contracts.
Patent Cost	Patent Costs
	The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations.
Property and Equipment	Property and Equipment
	Property and equipment, including leasehold improvements, are stated at cost or, if the assets are impaired, at fair value. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are generally as follows: five years for machinery and equipment; seven years for furniture and fixtures; three years for office equipment; and three years for computer equipment and software. Leasehold improvements are amortized over the shorter of their useful lives or the terms of the related leases. Asset lives are reviewed periodically to determine if appropriate and adjustments are made as necessary. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are expensed as incurred.
	For the years ended December 31, 2014, 2013 and 2012, the Company recorded depreciation expense on its property and equipment of $49,000, $12,000 and $30,000, respectively.
Comprehensive Income (Loss)	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Components of comprehensive income (loss) includes, among other items, unrealized gains and losses on the changes in fair value of investments and foreign currency translation adjustments for entities not using the U.S. Dollar as their functional currency. These components are added, net of their related tax effect, to the reported net income (loss) to arrive at comprehensive income (loss). The components of accumulated other comprehensive income at December 31, 2014, on the Company’s consolidated balance sheet was comprised of the net unrealized net holding gains on the Company’s investments in marketable securities and foreign currency translation adjustments related to the consolidation of the Company’s variable interest entity which does not use the U.S. Dollar as its function currency. There was no similar accumulated other comprehensive income or loss components at December 31, 2013 and 2012. See Note 4 for further detail of the unrealized holdings gains and losses on the Company’s investments in marketable securities and Note 9 for further detail of the Company’s variable interest entity.
Concentration Risk	Concentration Risk
	Credit Risk. Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain safety and liquidity. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, restricted cash and marketable securities.
	Manufacturing. The Company depends on an outsourced manufacturing strategy for its product candidates. It currently has a single source of supply for its drugs substance and has a single manufacturer for its drug product. If the Company’s third-party manufacturers are unable to manufacture its products, or if its suppliers or third-party manufacturers decide they no longer want to manufacture its products, the Company may need to find alternative manufacturing facilities, which would be time-consuming and significantly impact its ability to develop, obtain regulatory approval for or market our products.
Net Loss per Share	Net Loss per Share
	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, unvested restricted common stock subject to repurchase, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for all periods presented.
	The actual net loss per shares amounts for the years presented were computed based on the weighted average shares of common stock outstanding during the respective periods and includes the effect of the (1) 8,050,000 common shares issues pursuant to the initial public offering in February 2014; and (2) 3,622,500 common shares issued pursuant to the follow-on offering in the third quarter of 2014. As a result of the issuance of these common shares, there is a lack of comparability in the basic and diluted net loss per share amounts for the periods presented. See Note 8 for further discussion.
	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		Year Ended December 31,
		2014		2013		2012
	Convertible preferred stock		—		14,937,836		9,109,868
	Warrants to purchase convertible preferred stock		—		859,743		824,944
	Warrants to purchase common stock		547,089		—		—
	Common stock options		1,992,012		986,111		512,228
	Common stock subject to repurchase		624,710		955,555		—
			3,163,811		17,739,245		10,447,040
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. A valuation allowance is recorded when it is more likely than not that some, or all, of the deferred tax assets will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies.
	The Company assesses its income tax positions and record tax benefits for all years subject to examination based upon its evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, the Company has recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, Development State Entities, which eliminates the financial reporting distinction between development stage entities and other reporting entities, thereby eliminating the requirements to present inception-to-date information in the statements of operations and stockholders’ equity and cash flow, or label the financial statements as those of a development stage entity. The Company has elected to early adopt this guidance, as permitted, for its financial statements for the year ended December 31, 2014, and therefore has no longer labeled its consolidated financial statements as those of a development stage entity or included any inception-to-date information.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 requires management to perform interim and annual assessments on whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year of the date the financial statements are issued. If such conditions or events exist, certain disclosures are required. ASU No. 2014-15 is effective prospectively for fiscal years beginning after beginning December 15, 2016 and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of the pending adoption of ASU No. 2014-15 on its consolidated financial statements and related disclosures.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Weighted Average of Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model	The following table summarizes the weighted-average estimates the Company used in the Black-Scholes option pricing model for the years ended December 31, 2014, 2013 and 2012, to determine the grant-date fair value of stock options granted during each period for its stock option awards:
		Year Ended December 31,
		2014		2013		2012
	Risk free interest rate		1.40%		1.50%		1.00%
	Expected life in years	6.2 years		6.1 years		6.0 years
	Expected dividend yield		0.00%		0.00%		0.00%
	Expected volatility		87.20%		82.60%		94.30%
Summary of Weighted Average Inputs Used for ESPP Determined Using Black-Scholes Option Pricing Model	The Black-Scholes inputs are determined in the same manner as for stock options and the weighted-average inputs used for the ESPP for the year ended December 31, 2014, were as follows:
		Year Ended December 31, 2014
	Risk free interest rate		0.20%
	Expected life in years	1.3 years
	Expected dividend yield		0.00%
	Expected volatility		82.00%
Summary of Total Stock-Based Compensation Expense Included in Statements of Operations for Stock Options and ESPP	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options, restricted stock and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Year Ended December 31,
		2014		2013		2012
	Research and development	$	1,832	$	89	$	43
	General and administrative		1,975		211		39
	Total stock-based compensation expense	$	3,807	$	300	$	82
Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		Year Ended December 31,
		2014		2013		2012
	Convertible preferred stock		—		14,937,836		9,109,868
	Warrants to purchase convertible preferred stock		—		859,743		824,944
	Warrants to purchase common stock		547,089		—		—
	Common stock options		1,992,012		986,111		512,228
	Common stock subject to repurchase		624,710		955,555		—
			3,163,811		17,739,245		10,447,040

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 and 2013, are as follows (in thousands):
					Fair Value Measurements Using
		Balance as of December 31, 2014			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Money market funds(1)	$	20,371		$	20,371	$	—	$	—
	Commercial paper		26,325			—		26,325		—
	Corporate debt securities(2)		93,433			—		93,433		—
	Total	$	140,129		$	20,371	$	119,758	$	—
	-1	Included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.
	-2	Corporate debt securities purchased within three months of maturity valued at $4,610 is included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.
					Fair Value Measurements Using
		Balance as of December 31, 2013			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Series C preferred stock warrants	$	1,165		$	—	$	—	$	1,165
	Series D preferred stock warrants		2,330			—		—		2,330
	Series E preferred stock warrants		480			—		—		480
	Total	$	3,975		$	—	$	—	$	3,975
Assumptions used to Determine Fair Value of Convertible Preferred Stock Warrant Liability	The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrant liability as of February 10, 2014, the conversion date, and December 31, 2013:
		February 10,			December 31,
		2014			2013
	Risk-free interest rate	0.07%-2.64%			0.07%-3.04%
	Expected dividend yield		0%			0%
	Expected volatility	69.66%-87.51%			66.49%-85.10%
	Expected term (in years)	0.29-9.89			0.39-9.99
Reconciliation of all Liabilities Measured at Fair Value Using Level Three Significant Unobservable Inputs	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Warrant
		Liability
	Balance at January 1, 2013	$	1,556
	Issuance of warrants		606
	Exercise of tranche rights		(118	)
	Change in fair value(1)		1,931
	Balance at December 31, 2013		3,975
	Change in fair value(1)		3,634
	Reclassification of warrants(2)		(7,609	)
	Balance as of December 31, 2014	$	—
	-1	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.
	-2	In connection with the completion of the Company’s IPO in February 2014, the Company reclassified the warranty liability to stockholders’ equity as the warrants met the definition of an equity instrument under derivative accounting guidance.

Investments_in_Marketable_Secu1

Investments in Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Summary of Investments Classified as Available-For-Sale Securities	Investments classified as available-for-sale at December 31, 2014, consisted of the following (in thousands):
		Maturity	Amortized		Gross		Gross			Aggregate
		(in years)	Cost		Unrealized		Unrealized			Estimated
					Gains		Losses			Fair Value
	Marketable Securities:
	Corporate debt securities(1)	1 year or less	$	93,470	$	2	$	(39	)	$	93,433
	Commercial paper(1)	1 year or less		21,673		42		—			21,715
	Total available-for-sale securities		$	115,143	$	44	$	(39	)	$	115,148
	(1)There were no securities scheduled to mature outside of one year at December 31, 2014.

Other_Balance_Sheet_Items_Tabl

Other Balance Sheet Items (Tables)	12 Months Ended
	Dec. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Summary of Prepaid and Other Current Assets	Prepaid and other current assets consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Prepaid clinical trial costs	$	4,568		$	—
	Prepaid insurance		203			72
	Interest receivable		567			—
	Prepaid other and other current assets		373			170
	Total	$	5,711		$	242
Summary of Property and Equipment Balances	Property and equipment consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Computer equipment and software	$	137		$	45
	Leasehold improvements		46			5
	Furniture and fixtures		43			16
	Office equipment		23			12
	Machinery and equipment		4			4
			253			82
	Less accumulated depreciation		(76	)		(56	)
	Total	$	177		$	26
Summary of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Clinical trial accruals	$	1,168		$	565
	Accrued personnel costs		2,679			475
	Manufacturing cost accrual		212			772
	Other accrued expenses		604			315
	Total	$	4,663		$	2,127

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Future Minimum Payments under Term Loan	Future minimum payments under the term loan are as follows (in thousands):
	Year Ending December 31,
	2015	$	1,350
	2016		7,650
	2017		8,223
	2018		1,135
	Total future minimum payments		18,358
	Less amounts representing interest and fees		(2,908	)
	Less end of term payment		(450	)
	Gross balance of long-term debt		15,000
	Less unamortized discount		(405	)
	Total present value of long-term debt		14,595
	Less current portion		—
	Long-term portion	$	14,595

Convertible_Preferred_Stock_Wa1

Convertible Preferred Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summary of Outstanding Convertible Preferred Stock Warrants and Corresponding Exercise Price	The following table summarizes the shares subject to outstanding warrants and the corresponding exercise price as of December 31, 2014 and 2013:
		Number of Shares Outstanding
		December 31,		December 31,		Exercise Price		Expiration Date
		2014		2013
	May 2009 Series C Warrants		—		507,910	$	0.862	22-May-14
	October 2009 Series C Warrants		—		464,035	$	0.862	9-Oct-14
	January 2010 Series C Warrants		—		457,285	$	0.862	8-Jan-15
	December 2011 Series D Warrants		—		654,292	$	0.862	15-Dec-16
	April 2012 Series D Warrants		—		654,291	$	0.862	20-Apr-07
	July 2012 Series D Warrants		—		348,027	$	0.862	18-Jul-17
	August 2012 Series D Warrants		—		348,027	$	0.862	28-Aug-17
	January 2013 Series D Warrants		—		174,014	$	0.862	9-Jan-23
	December 2013 Series E Warrants		—		261,020	$	1.724	27-Dec-23
	Common Stock Warrants		547,089		—	$	3.879
	Total		547,089		3,868,901

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summary of Shares Authorized, Available for Future Grant and Outstanding	The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans at December 31, 2014:
							Outstanding
									Nonvested
		Authorized			Available		Options		Restricted Shares
	2010 Equity Incentive Plan		2,744,764			—		1,361,345		608,968
	2014 Equity Incentive Plan		1,652,948			1,022,281		630,667		—
			4,397,712			1,022,281		1,992,012		608,968
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity as of December 31, 2014, and changes for the year then ended:
							Weighted-
					Weighted-		Average
					Average		Remaining		Aggregate
					Exercise		Contractual		Intrinsic
		Shares			Price		Life (in Years)		Value
	Options outstanding at beginning of period		986,111		$	0.73
	Granted		1,278,646		$	15.87
	Exercised		(254,717	)	$	0.89
	Cancelled		(18,028	)	$	14.66
	Options outstanding at end of period		1,992,012		$	10.3		8.89	$	84,027,000
	Options exercisable at end of period		259,974		$	1.5		8.07	$	13,253,800
Summary of Restricted Share Activity	The following table further summarizes the Company’s restricted share activity as of December 31, 2014, and changes for the year then ended:
					Weighted-
					Average		Aggregate
					Grant Date		Intrinsic
		Shares			Fair Value		Value
	Nonvested restricted shares at beginning of period		933,333		$	0.54
	Vested		(324,365	)	$	0.54
	Nonvested restricted shares end of period		608,968		$	0.54	$	31,905,000
Summary of Employee Stock Purchase Plan Activity	The following table further summarizes the Company’s ESPP activity as of December 31, 2014, and changes for the year then ended:
		Shares
	Shares authorized for issuance under the 2014 ESPP at beginning of period		—
	Shares authorized in February 2014		300,000
	May purchase		(7,895	)
	November purchase		(16,720	)
	Shares authorized for issuance under the 2014 ESPP at end of period		275,385
Summary of Common Stock Reserved for Issuance Under Equity Plans	Total common stock reserved for issuance under our equity plans, ESPP and pursuant to outstanding warrants as of December 31, 2014, was as follows:
		Shares
	Warrants to purchase common stock outstanding		547,089
	Stock options outstanding		1,992,012
	Early exercise of stock options subject to repurchase		15,742
	Nonvested restricted shares subject to repurchase		608,968
	Equity plan shares authorized for future awards		1,022,281
	ESPP shares authorized for issuance		275,385
			4,461,477

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum payments as of December 31, 2014, pursuant to the Fourth and Fifth Amendments, are as follows (in thousands):
	Year Ending December 31,
	2015	$	860
	2016		1,140
	2017		1,175
	2018		1,211
	2019		1,246
	2020		319
	Total minimum lease payments	$	5,951

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Deferred Tax Assets for Federal and State Income Taxes	Other significant components of the Company’s net deferred tax assets for federal and state income taxes at December 31, 2014 and 2013, are shown below (in thousands):
		As of  December 31,
		2014			2013
	Deferred tax assets:
	Capitalized research and development	$	6,093		$	7,409
	Accrued compensation		999			39
	Stock-based compensation		917			21
	Other, net		419			48
			8,428			7,517
	Valuation allowance for deferred tax assets		(8,428	)		(7,517	)
	Net deferred tax assets	$	—		$	—
Reconciliation of Effective Tax Rate and Federal Statutory Rate	A reconciliation of the Company’s effective tax rate and federal statutory rate is as follows:
		As of  December 31,
		2014		2013	2012
	Federal income taxes	34.00%		34.00%	34.00%
	State income taxes	4.60%		4.80%	5.10%
	Research and development credits	4.40%		3.30%	0.60%
	Change in valuation allowance	-1.50%		-17.40%	-24.20%
	Fair value adjustments	-2.20%		-5.00%	-0.40%
	Nondeductible interest	—		—	-3.30%
	Removal of net operating loss and research and development tax credits	-38.10%		-18.90%	-11.40%
	Nondeductible expenses and other	-1.20%		-0.80%	-0.40%
		0.00%		0.00%	0.00%

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Data	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Selected quarterly financial data for years ended December 31, 2014 and 2013, are as follows (in thousands, except share and per share amounts):
		Fiscal Year 2014 Quarters
		1st(3)			2nd			3rd(4)			4th(5)			TOTAL
	Operating loss	$	(6,106	)	$	(10,039	)	$	(13,909	)	$	(20,202	)	$	(50,256	)
	Net loss	$	(10,123	)	$	(10,385	)	$	(19,025	)	$	(20,002	)	$	(59,535	)
	Net income attributed to noncontrolling interest	$	—		$	—		$	13		$	26		$	39
	Net loss attributable to Auspex shareholders	$	(10,123	)	$	(10,385	)	$	(19,038	)	$	(20,028	)	$	(59,574	)
	Basic and diluted net loss per share(1)(2)	$	(0.81	)	$	(0.45	)	$	(0.73	)	$	(0.74	)	$	(2.68	)
		Fiscal Year 2013 Quarters
		1st			2nd			3rd			4th			TOTAL
	Operating loss	$	(2,630	)	$	(2,817	)	$	(2,837	)	$	(4,908	)	$	(13,192	)
	Net loss	$	(2,305	)	$	(2,889	)	$	(2,846	)	$	(7,589	)	$	(15,629	)
	Net income attributed to noncontrolling interest	$	—		$	—		$	—		$	—		$	—
	Net loss attributable to Auspex shareholders	$	(2,305	)	$	(2,889	)	$	(2,846	)	$	(7,589	)	$	(15,629	)
	Basic and diluted net loss per share(1)(2)	$	(17,462	)	$	(21,886	)	$	(21,561	)	$	(46	)	$	(371	)
	-1	Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year.
	-2	In the first quarter of 2014, the Company issued 8,050,000 shares of common stock as part of its initial public offering. Further, the Company issued an additional 3,622,500 shares of common stock pursuant to a follow-on offering in July 2014. As a result, there is a lack of comparability in the basic and diluted net loss per share amount for the periods presented.
	-3	During the first quarter of 2014, in conjunction with the Company’s initial public offering, the Company recognized a change in the fair value of its convertible preferred stock warrants, resulting in a loss of $3,634.
	-4	During the third quarter of 2014, the Company recognized a $4,781 loss on the initial consolidation of the assets and liabilities of a VIE it began consolidating during the quarter.
	-5	During the fourth quarter of 2014, the Company recorded an adjustment to the loss on the initial consolidation of the VIE, reducing the loss by $512.

Organization_Additional_Inform

Organization - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounting Policies [Abstract]
Accumulated deficit	$125,054	$65,480

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	0 Months Ended	12 Months Ended					0 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended
	Jan. 16, 2014	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	Feb. 10, 2014	Mar. 31, 2014	Jul. 31, 2014	Sep. 30, 2014
		Segment
Summary Of Significant Accounting Policies [Line Items]
Number of operating segment		1
Reverse stock split, conversion ratio	0.22
Change in fair value of preferred stock warrant liability		$3,634,000	[1]	$1,931,000	[1]
Unrecognized stock based compensation expense		13,848,000
Unrecognized stock based compensation expense, weighted-average period		39 months
Depreciation		49,000		12,000		30,000
Accumulated other comprehensive income				0		0
Greater likelihood that tax benefit will be sustained percentage		50.00%
Lesser likelihood that tax benefit will be sustained percentage		50.00%
Income tax benefit		0
Machinery and Equipment
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		5 years
Furniture and Fixtures
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		7 years
Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		3 years
Computer Equipment and Software
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		3 years
Employee Stock Option Purchase Plan
Summary Of Significant Accounting Policies [Line Items]
Unrecognized stock based compensation expense		$253,000
Unrecognized stock based compensation expense, weighted-average period		7 months
Initial Public Offering
Summary Of Significant Accounting Policies [Line Items]
Stock issued during period, shares, new issues							8,050,000	8,050,000
Secondary Offering
Summary Of Significant Accounting Policies [Line Items]
Stock issued during period, shares, new issues									3,622,500	3,622,500
Stock Option Awards
Summary Of Significant Accounting Policies [Line Items]
Weighted average grant date fair value of options granted		$11.54		$0.55		$0.63
Restricted Stock Awards
Summary Of Significant Accounting Policies [Line Items]
Weighted average grant date fair value of options granted		$0		$0.54		$0
[1]	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Weighted Average Estimates Used in Black-Scholes Option Pricing Model (Details) (Stock Option Award)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option Award
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	1.40%	1.50%	1.00%
Expected life in years	6 years 2 months 12 days	6 years 1 month 6 days	6 years
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	87.20%	82.60%	94.30%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Weighted Average Inputs Used for ESPP Determined Using Black-Scholes Option Pricing Model (Details) (Employee Stock Option Purchase Plan)	12 Months Ended
	Dec. 31, 2014
Employee Stock Option Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	0.20%
Expected life in years	1 year 3 months 18 days
Expected dividend yield	0.00%
Expected volatility	82.00%

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Summary of Total Stock-Based Compensation Expense Included in Statements of Operations for Stock Options and ESPP (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$3,807	$300	$82
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	1,832	89	43
General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$1,975	$211	$39

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share	3,163,811	17,739,245	10,447,040
Convertible preferred stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share		14,937,836	9,109,868
Warrants to purchase convertible preferred stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share		859,743	824,944
Warrants to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share	547,089
Common stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share	1,992,012	986,111	512,228
Common stock subject to repurchase
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded in calculation of diluted net loss per share	624,710	955,555

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$140,129
Liabilities			3,975
Series C Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			1,165
Series D Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			2,330
Series E Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			480
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	93,433	[1]
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,371
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	119,758
Significant Other Observable Inputs (Level 2) | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	93,433	[1]
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			3,975
Significant Unobservable Inputs (Level 3) | Series C Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			1,165
Significant Unobservable Inputs (Level 3) | Series D Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			2,330
Significant Unobservable Inputs (Level 3) | Series E Preferred Stock Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities			480
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,371	[2]
Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,371	[2]
Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	26,325
Commercial Paper | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$26,325
[1]	Corporate debt securities purchased within three months of maturity valued at $4,610 is included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.
[2]	Included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.

Fair_Value_Measurements_Assets1

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$140,129
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	93,433	[1]
Fair Value, Measurements, Recurring | Cash and Cash Equivalents | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$4,610
[1]	Corporate debt securities purchased within three months of maturity valued at $4,610 is included within cash and cash equivalents on the Company’s consolidated balance sheet at December 31, 2014.

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumptions used to Determine Fair Value of Convertible Preferred Stock Warrant Liability (Details)	0 Months Ended	12 Months Ended
	Feb. 10, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate	0.07%	0.07%
Expected volatility	69.66%	66.49%
Expected term (in years)	3 months 15 days	4 months 21 days
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate	2.64%	3.04%
Expected volatility	87.51%	85.10%
Expected term (in years)	9 years 10 months 21 days	9 years 11 months 27 days

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of all Liabilities Measured at Fair Value Using Level Three Significant Unobservable Inputs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Fair Value Disclosures [Abstract]
Beginning Balance	$3,975,000		$1,556,000
Issuance of warrants			606,000
Exercise of tranche rights			-118,000
Change in fair value of preferred stock warrant liability	3,634,000	[1]	1,931,000	[1]
Reclassification of warrants	-7,609,000	[2]
Ending Balance	$0		$3,975,000
[1]	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.
[2]	In connection with the completion of the Company’s IPO in February 2014, the Company reclassified the warranty liability to stockholders’ equity as the warrants met the definition of an equity instrument under derivative accounting guidance.

Investments_in_Marketable_Secu2

Investments in Marketable Securities - Summary of Investments Classified as Available-for-Sale Securities (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	115,143
Gross Unrealized Gains	44
Gross Unrealized Losses	-39
Aggregate Estimated Fair Value	115,148
Long-term Investments | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	93,470	[1]
Gross Unrealized Gains	2	[1]
Gross Unrealized Losses	-39	[1]
Aggregate Estimated Fair Value	93,433	[1]
Long-term Investments | Corporate Debt Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Securities Debt Maturities Period	1 year	[1]
Short-term investments | Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	21,673	[1]
Gross Unrealized Gains	42	[1]
Aggregate Estimated Fair Value	21,715	[1]
Short-term investments | Commercial Paper | Maximum
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Securities Debt Maturities Period	1 year	[1]
[1]	There were no securities scheduled to mature outside of one year at December 31, 2014.

Investments_in_Marketable_Secu3

Investments in Marketable Securities - Summary of Investments Classified as Available-for-Sale Securities (Parenthetical) (Details) (USD $)	Dec. 31, 2014
Schedule Of Available For Sale Securities [Line Items]
Available For Sale Securities Scheduled to Mature Outside of one year Fair Value	$0

Investments_in_Marketable_Secu4

Investments in Marketable Securities - Summary of Investments Classified as Available-For-Sale Securities (Additional Information) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
	Security
Marketable Securities [Abstract]
Marketable securities	$115,148	$0
Number of security in an unrealized loss position for less than 12 months	23
Gains or losses on sales or maturities of available-for-sale securities	$0

Other_Balance_Sheet_Items_Summ

Other Balance Sheet Items - Summary of Prepaid and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid clinical trial costs	$4,568
Prepaid insurance	203	72
Interest receivable	567
Prepaid other and other current assets	373	170
Prepaid expenses and other current assets	$5,711	$242

Other_Balance_Sheet_Items_Summ1

Other Balance Sheet Items - Summary of Property and Equipment Balances (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Line Items]
Property and equipment, gross	$253	$82
Less accumulated depreciation	-76	-56
Property and equipment, net	177	26
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	137	45
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	46	5
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	43	16
Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	23	12
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$4	$4

Other_Balance_Sheet_Items_Summ2

Other Balance Sheet Items - Summary of Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities Current And Noncurrent [Abstract]
Clinical trial accruals	$1,168	$565
Accrued personnel costs	2,679	475
Manufacturing cost accrual	212	772
Other accrued expenses	604	315
Total accrued liabilities	$4,663	$2,127

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Details) (USD $)	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity	$15,000,000	$15,000,000
Credit facility fixed interest rate	8.99%
Debt instrument, interest payment period	12 months	6 months
Debt instrument, principal and interest payment period	36 months	24 months
Debt instrument maturity date	1-Jan-18
Percentage of original principal balance of loan to be paid to lenders	3.00%
Debt issuance costs	$100,000
Interest-only payments start date		1-Jan-16
Interest-only period		30 months
Debt maturities prepayment terms		The Company is permitted to make voluntary prepayments of the term loan with a prepayment fee equal to (i) 3% of the term loan prepaid during the first 12 months, (ii) 2% of the term loan prepaid in months 13-24 and (iii) 1% of the term loan prepaid thereafter.
Percentage of prepayment fee for twelve months		3.00%
Percentage of prepayment fee for thirteen to twenty four months		2.00%
Percentage of prepayment fee thereafter		1.00%
Revised Period
Debt Instrument [Line Items]
Debt instrument, principal and interest payment period		30 months
Debt Instrument Interest payment extended period		18 months

LongTerm_Debt_Future_Minimum_P

Long-Term Debt - Future Minimum Payments under Term Loan (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$1,350
2016	7,650
2017	8,223
2018	1,135
Total future minimum payments	18,358
Less amounts representing interest and fees	-2,908
Less end of term payment	-450
Gross balance of long-term debt	15,000	15,000
Less unamortized discount	-405
Total present value of long-term debt	14,595
Long-term portion	$14,595	$14,420

Convertible_Preferred_Stock_Wa2

Convertible Preferred Stock Warrants - Additional Information (Details) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended	1 Months Ended
	31-May-14	Jan. 16, 2014	Oct. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2013
Class Of Warrant Or Right [Line Items]
Reverse stock split, conversion ratio		0.22
Aggregate shares pursuant to warrants issued				763,073	547,089	547,089	3,868,901
Per share exercise price of warrants issued				$3.88
Warrants exercised into common shares	112,867		103,117
Common stock issued, net	100,467		86,237
Initial Public Offering
Class Of Warrant Or Right [Line Items]
Per share exercise price of warrants issued				$7.76
Warrants exercised into common shares				58,001
Jan-13
Class Of Warrant Or Right [Line Items]
Per share exercise price of warrants issued				$3.88
Warrants exercised into common shares				38,669
Common stock issued, net				33,469
Issuance of warrants in purchase of Preferred Stock								174,014
Issuance price of Preferred stock								$0.86
Series C Preferred Stock
Class Of Warrant Or Right [Line Items]
Aggregate shares pursuant to warrants issued							1,429,230
Series D convertible preferred stock
Class Of Warrant Or Right [Line Items]
Aggregate shares pursuant to warrants issued							2,004,637
Series E convertible preferred stock
Class Of Warrant Or Right [Line Items]
Issuance of warrants in purchase of Preferred Stock							261,020
Issuance price of Preferred stock							1.724
Expiration date of warrants					27-Dec-23
Estimated fair value of Warrants at issuance date					$480,000	480,000
Common Stock Warrant
Class Of Warrant Or Right [Line Items]
Reverse stock split, conversion ratio		1
Aggregate shares pursuant to warrants issued					547,089	547,089
Common Stock Warrant | Initial Public Offering
Class Of Warrant Or Right [Line Items]
Common stock issued, net						49,721
Series D Warrants | January 2013
Class Of Warrant Or Right [Line Items]
Aggregate shares pursuant to warrants issued							174,014
Per share exercise price of warrants issued							0.862
Expiration date of warrants					9-Jan-23

Convertible_Preferred_Stock_Wa3

Convertible Preferred Stock Warrants - Summary of Outstanding Convertible Preferred Stock Warrants and Corresponding Excercise Price (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 28, 2014	Dec. 31, 2013
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding	547,089	763,073	3,868,901
Per share exercise price of warrants issued		$3.88
Common Stock Warrant
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding	547,089
Common Stock Warrant | Minimum
Class Of Warrant Or Right [Line Items]
Per share exercise price of warrants issued	$3.88
Common Stock Warrant | Maximum
Class Of Warrant Or Right [Line Items]
Per share exercise price of warrants issued	$7.76
May 2009 | Series C Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			507,910
Per share exercise price of warrants issued			0.862
Expiration date of warrants	22-May-14
October 2009 | Series C Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			464,035
Per share exercise price of warrants issued			0.862
Expiration date of warrants	9-Oct-14
January 2010 | Series C Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			457,285
Per share exercise price of warrants issued			0.862
Expiration date of warrants	8-Jan-15
December 2011 | Series D Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			654,292
Per share exercise price of warrants issued			0.862
Expiration date of warrants	15-Dec-16
April 2012 | Series D Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			654,291
Per share exercise price of warrants issued			0.862
Expiration date of warrants	20-Apr-07
July 2012 | Series D Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			348,027
Per share exercise price of warrants issued			0.862
Expiration date of warrants	18-Jul-17
August 2012 | Series D Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			348,027
Per share exercise price of warrants issued			0.862
Expiration date of warrants	28-Aug-17
Jan-13
Class Of Warrant Or Right [Line Items]
Per share exercise price of warrants issued		$3.88
January 2013 | Series D Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			174,014
Per share exercise price of warrants issued			0.862
Expiration date of warrants	9-Jan-23
December 2013 | Series E Warrants
Class Of Warrant Or Right [Line Items]
Number of Shares Outstanding			261,020
Per share exercise price of warrants issued			1.724
Expiration date of warrants	27-Dec-23

Stockholders_Equity_Initial_Pu

Stockholders' Equity - Initial Public Offering and Related Transactions - Additional Information (Details) (USD $)	0 Months Ended	12 Months Ended			3 Months Ended	1 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended
	Feb. 10, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Jul. 31, 2014	Sep. 30, 2014	Jan. 15, 2014	Feb. 28, 2014
		Installment
Stockholders Equity Note [Line Items]
Convertible Preferred stock, shares authorized		10,000,000	68,694,006						10,000,000
Convertible Preferred stock, par value		$0.00	$0.00						0.0001
Common stock, shares authorized		200,000,000	86,500,000						200,000,000
Common stock, par value		$0.00	$0.00						0.0001
Proceeds from the issuance of common stock, net of fees		$151,633,000	$9,000
Conversion of outstanding convertible preferred stock	14,397,836
Number of Shares Outstanding		547,089	3,868,901						763,073
Shares authorized for issuance		3,059,326
Early exercise of stock options subject to repurchase		15,742
Stock options granted expire period		10 years
Options granted vesting period		4 years
Stock option vested percentage		25.00%
Number of installments for stock options		36
Exercise price of the stock options		100.00%
Incentive stock option granted stock holders		10.00%
Awards to the Board of Directors
Stockholders Equity Note [Line Items]
Options granted vesting period		1 year
Incentive Stock Option grants to 10% holders
Stockholders Equity Note [Line Items]
Exercise price of the stock options		110.00%
Employee Stock Option Plan
Stockholders Equity Note [Line Items]
Aggregate intrinsic value of options exercised		6,415,000	8,000
Proceeds from Stock Options Exercised		227,000
Exercise of stock options, shares		254,717		0
Restricted Shares
Stockholders Equity Note [Line Items]
Restricted shares granted		0	1,100,793	0
Restricted shares vested		324,365	491,825
Restricted shares unvested		608,968	933,333
Aggregate intrinsic value of restricted shares vested		6,362,000	1,000
Liabilities of shares subject to repurchase obligation		40,000	62,000
2014 Equity Incentive Plan
Stockholders Equity Note [Line Items]
Shares authorized for issuance									1,110,000
Conditions for issuance of stock reserved		The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1st of each year, from January 1, 2015 continuing through January 1, 2024, by 4% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors.
Annual increment in number of common stock shares reserved for issuance as a percentage of common stock shares outstanding		4.00%
2014 Equity Incentive Plan | Incentive Stock Option grants to 10% holders
Stockholders Equity Note [Line Items]
Maximum ISO shares to be issued under Plan		8,318,652
Convertible preferred stock
Stockholders Equity Note [Line Items]
Number of Shares Outstanding	3,868,901
Common Stock
Stockholders Equity Note [Line Items]
Number of Shares Outstanding	859,743
Initial Public Offering
Stockholders Equity Note [Line Items]
Stock issued during period, shares, new issues	8,050,000				8,050,000
Common stock offering price, per share	12
Proceeds from the issuance of common stock, net of fees	86,658,000
Secondary Offering
Stockholders Equity Note [Line Items]
Stock issued during period, shares, new issues						3,622,500	3,622,500
Common stock offering price, per share						$19.25
Proceeds from the issuance of common stock, net of fees						64,973,000
Employee Stock Option Purchase Plan
Stockholders Equity Note [Line Items]
Conditions for issuance of stock reserved		The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year, from January 1, 2015, continuing through January 1, 2024, by an amount equal to the lessor of (a) 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, (b) 530,000 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b).
Maximum amount eligible for employees to purchase share								$25,000
Offering price at discount rate for ESPP								85.00%
Shares authorized for issuance									300,000
Annual increment in number of common stock shares reserved for issuance								530,000
Employee Stock Option Purchase Plan | Scenario One
Stockholders Equity Note [Line Items]
Annual increment in number of common stock shares reserved for issuance as a percentage of common stock shares outstanding								1.00%

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Shares Authorized, Available for Future Grant and Outstanding (Details)	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance under Equity Incentive Plans	4,397,712
Shares available for issuance	1,022,281
Employee Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options	1,992,012	986,111
Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding nonvested restricted shares	608,968	933,333
2010 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance under Equity Incentive Plans	2,744,764
2010 Equity Incentive Plan | Employee Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options	1,361,345
2010 Equity Incentive Plan | Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding nonvested restricted shares	608,968
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance under Equity Incentive Plans	1,652,948
Shares available for issuance	1,022,281
2014 Equity Incentive Plan | Employee Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options	630,667

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Stock Option Activity (Details) (Employee Stock Option Plan, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Employee Stock Option Plan
Stock option activity rollforward
Share, Options outstanding at beginning of period	986,111
Share, Granted	1,278,646
Share, Exercised	-254,717	0
Share, Cancelled	-18,028
Share, Options outstanding at end of period	1,992,012
Share, Options exercisable at end of period	259,974
Weighted Average Exercise Price Rollforward
Weighted Average Exercise Price, Options outstanding at beginning of period	$0.73
Weighted Average Exercise Price, Granted	$15.87
Weighted Average Exercise Price, Exercised	$0.89
Weighted Average Exercise Price, Cancelled	$14.66
Weighted Average Exercise Price, Options outstanding at end of period	$10.30
Weighted Average Exercise Price, Options exercisable at end of period	$1.50
Weighted- Average Remaining Contractual Life (in Years)
Weighted Average Remaining Contractual Life, Options outstanding at end of period	8 years 10 months 21 days
Weighted Average Remaining Contractual Life, Options exercisable at end of period	8 years 26 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Options outstanding at end of period	$84,027,000
Aggregate Intrinsic Value, Options exercisable at end of period	$13,253,800

Stockholders_Equity_Summary_of2

Stockholders' Equity - Summary of Restricted Share Activity (Details) (Restricted Shares, USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Nonvested restricted shares at beginning of period	933,333
Shares, Vested	-324,365	-491,825
Shares, Nonvested restricted shares end of period	608,968	933,333
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at beginning of period	$0.54
Weighted-Average Grant Date Fair Value, Vested	$0.54
Weighted-Average Grant Date Fair Value, Nonvested restricted shares end of period	$0.54	$0.54
Aggregate Intrinsic Value, Nonvested restricted shares end of period	$31,905

Stockholders_Equity_Summary_of3

Stockholders' Equity - Summary of Employee Stock Purchase Plan Activity (Details)	1 Months Ended
	Nov. 30, 2014	31-May-14	Feb. 28, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance beginning of period				4,397,712
Shares authorized for issuance end of period				4,397,712
Employee Stock Option Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance beginning of period				275,385
Shares authorized in February 2014			300,000
Shares purchased	-16,720	-7,895
Shares authorized for issuance end of period				275,385

Stockholders_Equity_Summary_of4

Stockholders' Equity - Summary of Common Stock Reserved for Issuance Under Equity Plans (Details)	Dec. 31, 2014	Feb. 28, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding	547,089	763,073	3,868,901
Early exercise of stock options subject to repurchase	15,742
Equity plan shares authorized for future awards	1,022,281
Shares authorized for issuance	4,397,712
Common stock reserved for issuance	4,461,477
Employee Stock Option Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance	275,385
Employee Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options outstanding	1,992,012		986,111
Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares unvested	608,968		933,333

Variable_Interest_Entity_Addit

Variable Interest Entity - Additional Information (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014
Variable Interest Entity Measure Of Activity [Abstract]
Loss on consolidation of variable interest entity	$512	$4,781	$4,269
Noncontrolling interest in variable interest entity	$3,784		$3,784

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Noncancelable operating lease for corporate office space	2011-06
Percentage of Royalty Payments	1.44%
Amendment One
Commitments And Contingencies [Line Items]
Lease entry period	2012-06
Amendment Two
Commitments And Contingencies [Line Items]
Lease entry period	2012-11
Amendment Three
Commitments And Contingencies [Line Items]
Lease entry period	2014-02
Amendment Four
Commitments And Contingencies [Line Items]
Lease entry period	2014-07
Additional space lease availability date	2015-01
Lease agreement amended date for extension period	2020-03
Amendment Four | Maximum
Commitments And Contingencies [Line Items]
Non-cancelable operating lease additional extension period	5 years
Amendment Four | Minimum
Commitments And Contingencies [Line Items]
Non-cancelable operating lease additional extension period	1 year
Amendment Five
Commitments And Contingencies [Line Items]
Lease entry period	2014-11

Commitments_Future_Minimum_Lea

Commitments - Future Minimum Lease Payments (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]
2015	$860
2016	1,140
2017	1,175
2018	1,211
2019	1,246
2020	319
Total minimum lease payments	$5,951

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation And Retirement Disclosure [Abstract]
Employees maximum annual contribution percentage	90.00%
Defined contribution plan, employer contribution amount	$0	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Accrued interest and/or related to income tax matters	$0	$0	$0
Interest and/or penalties expense	0	0	0
Percentage of change in cumulative ownership within three year	50.00%
Cumulative change in ownership period	3 years
Operating loss carryforwards, limitations on use	Annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event of a cumulative change in ownership of more than 50% within a three-year period.
Deferred tax assets for net operating losses	34,100,000
Research and development tax credit carryforwards	6,400,000
Employee Stock Option Plan
Income Tax Disclosure [Line Items]
Losses attributable to excess stock option deductions	6,000,000
Federal
Income Tax Disclosure [Line Items]
Research and development tax credit carryforwards	5,200,000
Net operating loss	91,200,000
Tax loss carryforwards expiration year	2021
Federal | Research and Development
Income Tax Disclosure [Line Items]
Tax credit carryforward expiration year	2021
State
Income Tax Disclosure [Line Items]
Research and development tax credit carryforwards	1,800,000
Net operating loss	$94,100,000
Tax loss carryforwards expiration year	2015

Income_Taxes_Components_of_Def

Income Taxes - Components of Deferred Tax Assets for Federal and State Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Capitalized research and development	$6,093	$7,409
Accrued compensation	999	39
Stock-based compensation	917	21
Other, net	419	48
Deferred tax assets, gross	8,428	7,517
Valuation allowance for deferred tax assets	($8,428)	($7,517)

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Tax Rate and Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal income taxes	34.00%	34.00%	34.00%
State income taxes	4.60%	4.80%	5.10%
Research and development credits	4.40%	3.30%	0.60%
Change in valuation allowance	-1.50%	-17.40%	-24.20%
Fair value adjustments	-2.20%	-5.00%	-0.40%
Nondeductible interest			-3.30%
Removal of net operating loss and research and development tax credits	-38.10%	-18.90%	-11.40%
Nondeductible expenses and other	-1.20%	-0.80%	-0.40%
Effective income tax rate reconciliation, total	0.00%	0.00%	0.00%

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Operating loss	($20,202)	[1]	($13,909)	[2]	($10,039)		($6,106)	[3]	($4,908)		($2,837)		($2,817)		($2,630)		($50,256)		($13,192)		($13,429)
Net loss	-20,002	[1]	-19,025	[2]	-10,385		-10,123	[3]	-7,589		-2,846		-2,889		-2,305		-59,535		-15,629		-15,112
Net income attributed to noncontrolling interest	26	[1]	13	[2]													39
Net loss attributable to Auspex shareholders	($20,028)	[1]	($19,038)	[2]	($10,385)		($10,123)	[3]	($7,589)		($2,846)		($2,889)		($2,305)		($59,574)		($15,629)		($15,112)
Basic and diluted net loss per share	($0.74)	[1],[4],[5]	($0.73)	[2],[4],[5]	($0.45)	[4],[5]	($0.81)	[3],[4],[5]	($46)	[4],[5]	($21,561)	[4],[5]	($21,886)	[4],[5]	($17,462)	[4],[5]	($2.68)	[4],[5],[6]	($371)	[4],[5],[6]	($114,485)	[6]
[1]	During the fourth quarter of 2014, the Company recorded an adjustment to the loss on the initial consolidation of the VIE, reducing the loss by $512.
[2]	During the third quarter of 2014, the Company recognized a $4,781 loss on the initial consolidation of the assets and liabilities of a VIE it began consolidating during the quarter.
[3]	During the first quarter of 2014, in conjunction with the Company’s initial public offering, the Company recognized a change in the fair value of its convertible preferred stock warrants, resulting in a loss of $3,634.
[4]	Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year.
[5]	In the first quarter of 2014, the Company issued 8,050,000 shares of common stock as part of its initial public offering. Further, the Company issued an additional 3,622,500 shares of common stock pursuant to a follow-on offering in July 2014. As a result, there is a lack of comparability in the basic and diluted net loss per share amount for the periods presented.
[6]	As a result of the issuance of common stock pursuant to public offerings in the first and third quarters of 2014, there is a lack of comparability in the per share amounts between the periods presented. Please see Note 2 of the Notes to Consolidated Financial Statements for further discussion.

Selected_Quarterly_Financial_D3

Selected Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Parenthetical) (Details) (USD $)	3 Months Ended			12 Months Ended			0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 10, 2014	Jul. 31, 2014
Quarterly Financial Information [Line Items]
Change in fair value of preferred stock warrant liability			$3,634	$3,634	$1,931	$195
Loss on consolidation of variable interest entity	$512	$4,781		$4,269
Initial Public Offering
Quarterly Financial Information [Line Items]
Stock issued during period, shares, new issues			8,050,000				8,050,000
Secondary Offering
Quarterly Financial Information [Line Items]
Stock issued during period, shares, new issues		3,622,500						3,622,500

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (USD $)	12 Months Ended		1 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014	Sep. 30, 2014	Jan. 31, 2015	Jan. 31, 2015
Subsequent Event [Line Items]
Proceeds from the issuance of common stock, net of fees	$151,633	$9
Secondary Offering
Subsequent Event [Line Items]
Stock issued during period, shares, new issues			3,622,500	3,622,500
Common stock offering price, per share			$19.25
Proceeds from the issuance of common stock, net of fees			64,973
Subsequent Event [Member]
Subsequent Event [Line Items]
Share purchase agreement date					31-Jan-15
Subsequent Event [Member] | Secondary Offering
Subsequent Event [Line Items]
Stock issued during period, shares, new issues						3,600,000
Common stock offering price, per share					56.5	$56.50
Proceeds from the issuance of common stock, net of fees						$190,496
Sale of common stock by existing stock holders						1,000,000
Sale of common stock including sales by existing stock holders						4,600,000